Why the study?
Does Ivabradine on top of background therapy improve clinical outcomes and quality of life in patients with heart failure?
Does Ivabradine on top of background therapy improve clinical outcomes and quality of life in patients with heart failure?
A systematic review confirms that ivabradine added to background therapy improves multiple clinical and functional outcomes in heart failure patients without increasing adverse events.
Answers are grounded in this paper and cite their sources.
Supports ivabradine addition in HF; confirms outcome benefits and safety in Level 1 synthesis.
Ivabradine on top of background therapy is beneficial for heart rate, hospitalization risk for HF, mortality, EF, and patients' QoL. Moreover, these benefits were achieved with no significant increase in the overall risk of total adverse events.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: